Wexford Science & Technology

Developer of a frameless, non-hormonal intrauterine contraceptive device designed to improve women's reproductive health by addressing pain and usability challenges associated with traditional intrauterine contraceptive devices (IUDS). The company's platform features a magnetic, copper-encased IUD composed of elliptical units that self-assemble in the uterus, paired with patented inserter and retriever devices engineered for string-free placement and removal, enabling women of reproductive age to access contraception to minimise insertion pain and eliminate common barriers to adoption in clinical and personal settings.

Developer of a frameless, non-hormonal intrauterine contraceptive device designed to improve women's reproductive health by addressing pain and usability challenges associated with traditional intrauterine contraceptive devices (IUDS). The company's platform features a magnetic, copper-encased IUD composed of elliptical units that self-assemble in the uterus, paired with patented inserter and retriever devices engineered for string-free placement and removal, enabling women of reproductive age to access contraception to minimise insertion pain and eliminate common barriers to adoption in clinical and personal settings.

Capsulomics, LLC is a biotechnology company focused on developing and manufacturing DNA tests for the early detection of upper gastrointestinal (GI) cancers, particularly esophageal cancer and its precancerous condition, Barrett’s esophagus. Founded in 2018 and based in Halethorpe, Maryland, Capsulomics aims to address the diagnostic and prognostic uncertainties associated with GI diseases. By providing advanced diagnostic solutions, the company enables healthcare professionals to prevent, detect, and treat these conditions more effectively, ultimately enhancing patient outcomes.